Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 8, 2005, Pages 3382-3386

  Macía, María D ^a   Blanquer, David ^b   Togores, Bernat ^b   Sauleda, Jaume ^b   Pérez, José L ^a   Oliver, Antonio ^a,b  

^a Servicio de Microbiologia   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; MEROPENEM; TOBRAMYCIN;

ADAPTATION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; GENETIC COMPLEMENTATION; HUMAN; LUNG INFECTION; MISMATCH REPAIR; MULTIDRUG RESISTANCE; MUTATION RATE; MUTS GENE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS;

ADENOSINE TRIPHOSPHATASES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BRONCHIECTASIS; CHRONIC DISEASE; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MUTS DNA MISMATCH-BINDING PROTEIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 23044473638     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.8.3382-3386.2005     Document Type: Article

References (46)

1. Blazquez, J. 2003. Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin. Infect. Dis. 37:1201-1209.
2. Celli, B. R., and W. MacNce. 2004. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 23:932-946.
3. Chopra, I., A. J. O'Neill, and K. Miller. 2003. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug. Resist. Updates 6:137-145.
4. CLSI. 2005. Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement, M100-S15. CLSI, Wayne, Pa.
5. Evans, S. A., S. M. Turner, B. J. Bosch, C. C. Hardy, and M. A. Woodhead. 1996. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur. Respir. J. 9:1601-1604.
6. Fish, D. N., S. C. Piscitelli, and L. H. Danziger. 1995. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15:279-291.
7. Gibson, R. L., J. L. Burns, and B. W. Ramsey. 2003. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168:918-951.
8. Giraud, A., I. Matic, O. Tenaillon, A. Clara, M. Radman, M. Fons, and F. Taddei. 2001. Costs and benefits of high mutation rates: adaptive evolution of bacteria in the mouse gut. Science 291:2606-2608.
9. Govan, J. R. W., and V. Deretic. 1996. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60:539-574.
10. Gutiérrez, O., C. Juan, J. L. Pérez, and A. Oliver. 2004. Lack of association between hypermutation and antibiotic resistance development in Pseudomonas aeruginosa isolates from intensive care unit patients. Antimicrob. Agents Chemother. 48:3573-3575.
11. Haussler, S., B. Tummler, H. Weissbrodt, M. Rohde, and I. Steinmetz. 1999. Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin. Infect. Dis. 29:621-625.
12. Henwood, C. J., D. M. Livermore, D. James, M. Warner, and the Pseudomonas Study Group. 2001. Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British society for antimicrobial chemotherapy disc susceptibility test. J. Antimicrob. Chemother. 47:789-799.
13. Hill, A. T., E. J. Campbell, S. L. Hill, D. L. Bayley, and R. A. Stockley. 2000. Markers of airway inflammation in patients with stable chronic bronchitis. Am. J. Med. 109:288-295.
14. Hla, S. W., K. P. Hui, W. C. Tan, and B. Ho. 1996. Genome macrorestriction analysis of sequential Pseudomonas aeruginosa isolates from bronchiectasis patients without cystic fibrosis. J. Clin. Microbiol. 34:575-578.
15. Horst, J. P., T. H. Wu, and M. G. Marinus. 1999. Escherichia coli mutator genes. Trends Microbiol. 7:29-36.
16. Rang, E. Y., R. R. Miller, and N. L. Müller. 1995. Bronchiectasis: comparison of preoperative thin-section CT and pathologic findings in resected specimens. Radiology 195:649-654.
17. Kaufmann, M. E. 1998. Pulsed-field gel electrophoresis. Methods Mol. Med. 15:17-31.
18. LeClerc, J. E., B. Li, W. L. Payne, and T. A. Cebula. 1996. High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 274: 1208-1211.
19. Lieberman, D., and D. Lieberman. 2003. Pseudomonal infections in patients with COPD: epidemiology and management. Am. J. Respir. Med. 2:459-468.
20. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.
21. Lyczak, J. B., C. L. Cannon, and G. B. Pier. 2002. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15:194-222.
22. Lynch, J. P. 2001. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 119(Suppl. 2):373-384.
23. Maciá, M. D., N. Borrell, J. L. Pérez, and A. Oliver. 2004. Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion. Antimicrob. Agents Chemother. 48:2665-2672.
24. Matic, I., M. Radman, F. Taddei, B. Picard, C. Doit, E. Bingen, E. Denamur, and J. Elion. 1997. High variable mutation rates in commensal and pathogenic Escherichia coli. Science 277:1833-1834.
25. Miller, J. H. 1996. Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair. Annu. Rev. Microbiol. 50:625-643.
26. Nagaki, M., S. Shimura, Y. Tanno, T. Ishibashi, H. Sasaki, and T. Takishima. 1992. Role of chronic Pseudomonas aeruginosa infection in the development of bronchiectasis. Chest 102:1464-1469.
27. Naidich, D. P., D. I. McCauley, H. F. Khouri, F. P. Stitik, and S. S. Siegelman. 1982. Computed tomography of bronchiectasis. J. Comput. Assisted Tomogr. 6:437-444.
28. Nicotra, M. B., M. Rivera, A. M. Dale, R. Shepherd, and R. Carter. 1995. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 108:955-961.
29. Oliver, A., R. Cantón, P. Campo, F. Baquero, and J. Blázquez. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1253.
30. Oliver, A., F. Baquero, and J. Blazquez. 2002. The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol. Microbiol. 43:1641-1650.
31. Oliver, A., B. R. Levin, C. Juan, F. Baquero, and J. Blázquez. 2004. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob. Agents Chemother. 48:4226-4233.
32. Prunier, A. L., B. Malbruny, M. Laurans, J. Brouard, J. F. Duhamel, and R. Leclerc. 2003. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J. Infect. Dis. 187:1709-1716.
33. Pujana, I., L. Gallego, G. Martin, F. López, J. Canduela, and R. Cisterna. 1999. Epidemiological analysis of sequential Pseudomonas aeruginosa isolates from chronic bronchiectasis patients without cystic fibrosis. J. Clin. Microbiol. 37:2071-2073.
34. Ramsey, B. W., H. L. Dorkin, J. D. Eisenberg, R. L. Gibson, I. R. Harwood, R. M. Kravitz, D. V. Schidlow, R. W. Wilmott, S. J. Astley, M. A. McBurney, K. Wentz, and A. L. Smith. 1993. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 328:1740-1746.
35. Ratjen, F., G. Doring, and W. Nikolaizik. 2001. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 358:983-984.
36. Richardson, A., R. Z. Yu, T. Popovic, and I. Stojiljkovic. 2002. Mutator clones of Neisseria meningitidis in epidemic serogroup A disease. Proc. Natl. Acad. Sci. USA 99:6103-6107.
37. Román, F., R. Cantón, M. Pérez-Vázquez, F. Baquero, and J. Campos. 2004. Dynamics of long-term colonization of respiratory tract by Haemophilus inftuenzae in cystic fibrosis patients shows a marked increase in hypermutable strains. J. Clin. Microbiol. 42:1450-1459.
38. Romling, U., B. Feidler, J. Bobhammer, D. Grothues, J. Greipel, H. Von der Hardt, and B. Tummler. 1994. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J. Infect. Dis. 170:1616-1621.
39. Smania, A. M., I. Segura, R. J. Pezza, C. Becerra, I. Albesa, and C. E. Argarana. 2004. Emergence of phenotypic variants upon mismatch repair disruption in Pseudomonas aeruginosa. Microbiology 150:1327-1338.
40. Smith, A. W., and B. H. Iglewski. 1989. Transformation of Pseudomonas aeruginosa by electroporation. Nucleic Acids Res. 17:10509.
41. Sniegowski, P. D., P. J. Gerrish, and R. E. Lenski. 1997. Evolution of high mutation rates in experimental populations of E. coli. Nature 387:703-705.
42. Stover, C. K., X. Q. Pham, A. L. Erwin, S. D. Mizoguchi, P. Warrener, M. J. Hickey, F. S. Brinkman, W. O. Hufnagle, D. J. Kowalik, M. Lagrou, R. L. Garber, L. Goltry, E. Tolentino, S. Westbrock-Wadman, Y. Yuan, L. L. Brody, S. N. Coulter, K. R. Folger, A. Kas, K. Larbig, R. Lim, K. Smith, D. Spencer, G. K. Wong, Z. Wu, I. T. Paulsen, J. Reizer, M. H. Saier, R. E. Hancock, S. Lory, and M. V. Olson. 2000. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959-964.
43. Taddei, F., M. Radman, J. Maynard-Smith, B. Toupance, P. H. Gouyon, and B. Godelle. 1997. Role of mutator alleles in adaptive evolution. Nature 19:700-702.
44. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
45. Vincent, J. L. 2003. Nosocomial infections in adult intensive-care units. Lancet 361:2068-2077.
46. Wilson, C. B., P. W. Jones, C. J. O'Leary, D. M. Hansell, P. J. Cole, and R. Wilson. 1997. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur. Respir. J. 10:1754-1760.